Vanrx Pharmasystems makes the most technologically advanced aseptic filling machines for the pharmaceutical industry. Vanrx fill-finish machines use robotics, machine vision and gloveless isolator technologies to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies.
Vanrx is a privately owned company, founded in 2007. It is based in Burnaby, British Columbia, Canada, part of the Vancouver metropolitan area.
For the second year in a row, Deloitte has presented Vanrx Pharmasystems with its Technology Fast 50 and North American Technology Fast 500 awards in recognition of rapid revenue growth, entrepreneurial spirit and bold innovation.Read More
Chris is a globally recognized subject matter expert in aseptic pharmaceutical manufacturing. He has led teams in the development, implementation and regulatory acceptance of aseptic processes for complex injectable products in the fields of ophthalmology, oncology and reproductive health. Chris passionately believes in the need to modernize pharmaceutical manufacturing and regularly contributes his knowledge at ISPE and PDA events.
Ross’ experience in the design development and fabrication of novel pharmaceutical manufacturing equipment, including automation systems, has guided the development of Vanrx’s Aseptic Workcells. He has held the same position as many of Vanrx’s customers—being responsible for the planning and execution of capital projects and process technical transfers.
Greg has a proven track record of fostering technology adoption in complex technology markets. He has formulated strategy, marketed and sold technology products in rapidly growing technology companies for more than 25 years. He brings comprehensive experience in market development, complex B2B sales and professional services to Vanrx.
Myles has significant financial leadership and corporate development experience with high-growth technology companies. His financial management and strategic acumen has enabled the international commercialization of new technologies with both private and publicly-listed companies.
Jeff is the Founder and Chief Executive Officer of 18 Asset Management. He has more than 25 years of experience in the industry. Over his career, he has established himself as an internationally recognized authority on investment process best practices, having been invited on numerous occasions to speak before local, national and global investment audiences. Articles Jeff has co-authored have been published in leading industry publications. Throughout his career, Jeff has successfully delivered on investment mandates, developed successful investment teams and built client-oriented investment companies.
Mr. Vander Laan founded Trojan Technologies Inc. in 1976, acquiring the patent for a small ultraviolet device for private water supply applications. Building upon that concept he developed a company that is now a global leader in its field with revenues well in excess of $100 million per year. In 2004, Trojan Technologies Inc. (at the time a TSX listed company) was acquired by Danaher Corporation. Mr. Vander Laan has continued to work with Trojan Technologies Inc in the role of Senior Advisor. Prior to founding Trojan Technologies Inc., Mr. Vander Laan was Vice President of Canadian Cable Systems Limited (currently Rogers Cable Systems) from 1969 to 1977, where he was responsible for technical operations and personnel for the largest cable television company in Canada.
George has over 25 years of experience in the medical device industry. He takes a leadership role in the acquisition and development of novel medical device technologies. He has been responsible for the pre-clinical marketing of new drug delivery technologies to medical opinion leaders and major pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of pre-clinical studies. George has been granted several U.S. and international patents for medical devices for drug delivery and minimally invasive surgery. He holds a MBA from the Richard Ivey School of Business, where he currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management. George serves as Chairman of the Trudell Medical Limited Board of Directors. He is also owner and President of Perfuse Medtec Inc. a Canadian medical device market development company.
Paul has worked in the pharmaceutical industry for 40 years, most recently as Director of Global Aseptic Technology for Pfizer Global Technology Services. After retiring from Pfizer, he founded Pamigo Aseptic, a consultancy focusing on aseptic pharmaceutical manufacturing. Among Mr. Gold’s accomplishments is the co-invention of the Restricted Access Barrier System (RABS), a method for aseptic process separation and protection used globally in drug production facilities. His areas of expertise include sterile suspension processing, formulation development, equipment design, and product and process development for aseptically-produced sterile products.
CEO, President and Co-Founder
VP, Technical Services, Corporate Secretary and Co-Founder
Vanrx Pharmasystems Inc. is committed to achieving the highest level of operational excellence and customer satisfaction through continual improvements to the quality of our products and services.
Our quality objectives include:
1. Manufacturing safe, reliable and durable world class aseptic filling machines by incorporating innovative technologies.
2. Ensuring customer satisfaction by delivering required product quality, identification of market needs and ongoing customer communication.
3. Maintaining a collaborative, innovative, transparent and ethical work environment.
4. Understanding that we operate a knowledge based business, where the expertise in all of our team is critical to success.
5. Continuing to meet and improve upon the quality management system.
We develop technologies that enable every company to provide safe and affordable injectable medicines to the world.